市場調査レポート

商品コード

1422075

ナノバイオテクノロジーの世界市場：タイプ別、治療法別、技術別、用途別、エンドユーザー別、地域別、機会、予測、2017年～2031年

Nanobiotechnology Market Assessment, By Type, By Therapeutics, By Technology, By Application, By End-user, By Region, Opportunities and Forecast, 2017-2031F

出版日: 2024年02月07日
発行: Market Xcel - Markets and Data
ページ情報: 英文 228 Pages
納期: 3～5営業日

カスタマイズ可能

価格

PDF & Excel Printable (Single User License)

USD 4,500 661,455円

レポートPDFを1名の方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能です。印刷は無制限で可能です。Excelのデータがライセンスに含まれています。

PDF & Excel Printable (Corporate License)

USD 5,700 837,843円

レポートPDFを企業の１カ国の拠点のすべての方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能ですが、企業内部での利用に限定されます。ご利用に際しては、あらかじめ出版社の許諾を得る必要があります。詳細はお問合せください。印刷は可能です。Excelのデータがライセンスに含まれています。

PDF & Excel Printable (Custom Research License)

USD 8,200 1,205,318円

レポートPDFを企業の１カ国の拠点のすべての方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能です。印刷は無制限で可能です。Excelのデータがライセンスに含まれています。アナリストアワー100時間が含まれており、レポートのカスタマイズなどにご利用いただけます。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=146.99円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

世界のナノバイオテクノロジーの市場規模は、2023年に758億米ドルと評価され、2031年には1,431億米ドルに達すると予測されており、2024年から2031年の予測期間のCAGRは8.27%になるとみられています。技術の進歩は世界のナノバイオテクノロジー市場の成長を促進し、研究開発投資を拡大し、ヘルスケアと医療における用途を拡大し、個別化医療と正確なドラッグデリバリーシステムの必要性を増大させる。さらに、ナノテクノロジーとバイオテクノロジーの融合は、診断、治療、生物医学研究の進歩に火をつけ、市場拡大に大きく貢献しています。

世界のナノバイオテクノロジー市場の堅調な拡大は、様々な極めて重要な要因に依存しています。最も重要なのは、現在進行中の技術進歩が絶えず技術革新の限界を押し広げていることです。ナノスケールの科学と工学のブレークスルーは、ナノバイオテクノロジーの領域における新しいツールと方法論の出現を促進し、比類のない機会を解き放っています。同時に、多様なセクターにわたる研究開発（R&D）への投資の高まりが、ナノバイオテクノロジーの進化を後押ししています。こうした多額の投資は、新規の応用、材料、調査手法の探求を推進し、ヘルスケアと医療における画期的な発見の可能性を高めています。ヘルスケアと医療におけるナノテクノロジーの統合の増加は、世界のナノバイオテクノロジー市場を拡大するための支柱となっています。

これらの分野でのナノテクノロジーの適応性は、診断における顕著な進歩を促進し、早期疾病同定のための高感度で正確なツールを提供します。さらに、治療においては、ナノテクノロジーは、標的を定めて制御された薬物放出を可能にすることによってドラッグデリバリーシステムを変革し、副作用を最小限に抑えながら治療効果を向上させます。オーダーメイド医療と正確なドラッグデリバリーシステムに対する需要の高まりが、世界のナノバイオテクノロジー市場の成長をさらに後押ししています。治療と介入をカスタマイズするナノテクノロジーの能力は、高まるニーズと完全に合致しており、個人の明確な遺伝子組成や特定の健康状態に合わせた治療法の開発を促進しています。さらに、ナノテクノロジーとバイオテクノロジーの融合は触媒として機能し、診断、治療、生物医学研究におけるブレークスルーを促進します。この融合がイノベーションを促進し、ナノバイオテクノロジーの可能性の領域を拡大し、世界のナノバイオテクノロジー市場の拡大と進展に大きく貢献しています。

当レポートでは、世界のナノバイオテクノロジー市場について調査し、市場の概要とともに、タイプ別、治療法別、技術別、用途別、エンドユーザー別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

List of Tables

Table 1. Pricing Analysis of Products from Key Players
Table 2. Competition Matrix of Top 5 Market Leaders
Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

Figure 1. Global Nanobiotechnology Market, By Value, In USD Billion, 2017-2031F
Figure 2. Global Nanobiotechnology Market, By Volume, In Million Units, 2017-2031F
Figure 3. Global Nanobiotechnology Market Share (%), By Type, 2017-2031F
Figure 4. Global Nanobiotechnology Market Share (%), By Therapeutics, 2017-2031F
Figure 5. Global Nanobiotechnology Market Share (%), By Technology, 2017-2031F
Figure 6. Global Nanobiotechnology Market Share (%), By Application, 2017-2031F
Figure 7. Global Nanobiotechnology Market Share (%), By End-user, 2017-2031F
Figure 8. Global Nanobiotechnology Market Share (%), By Region, 2017-2031F
Figure 9. North America Nanobiotechnology Market, By Value, In USD Billion, 2017-2031F
Figure 10. North America Nanobiotechnology Market, By Volume, In Million Units, 2017-2031F
Figure 11. North America Nanobiotechnology Market Share (%), By Type, 2017-2031F
Figure 12. North America Nanobiotechnology Market Share (%), By Therapeutics, 2017-2031F
Figure 13. North America Nanobiotechnology Market Share (%), By Technology, 2017-2031F
Figure 14. North America Nanobiotechnology Market Share (%), By Application, 2017-2031F
Figure 15. North America Nanobiotechnology Market Share (%), By End-user, 2017-2031F
Figure 16. North America Nanobiotechnology Market Share (%), By Country, 2017-2031F
Figure 17. United States Nanobiotechnology Market, By Value, In USD Billion, 2017-2031F
Figure 18. United States Nanobiotechnology Market, By Volume, In Million Units, 2017-2031F
Figure 19. United States Nanobiotechnology Market Share (%), By Type, 2017-2031F
Figure 20. United States Nanobiotechnology Market Share (%), By Therapeutics, 2017-2031F
Figure 21. United States Nanobiotechnology Market Share (%), By Technology, 2017-2031F
Figure 22. United States Nanobiotechnology Market Share (%), By Application, 2017-2031F
Figure 23. United States Nanobiotechnology Market Share (%), By End-user, 2017-2031F
Figure 24. Canada Nanobiotechnology Market, By Value, In USD Billion, 2017-2031F
Figure 25. Canada Nanobiotechnology Market, By Volume, In Million Units, 2017-2031F
Figure 26. Canada Nanobiotechnology Market Share (%), By Type, 2017-2031F
Figure 27. Canada Nanobiotechnology Market Share (%), By Therapeutics, 2017-2031F
Figure 28. Canada Nanobiotechnology Market Share (%), By Technology, 2017-2031F
Figure 29. Canada Nanobiotechnology Market Share (%), By Application, 2017-2031F
Figure 30. Canada Nanobiotechnology Market Share (%), By End-user, 2017-2031F
Figure 31. Mexico Nanobiotechnology Market, By Value, In USD Billion, 2017-2031F
Figure 32. Mexico Nanobiotechnology Market, By Volume, In Million Units, 2017-2031F
Figure 33. Mexico Nanobiotechnology Market Share (%), By Type, 2017-2031F
Figure 34. Mexico Nanobiotechnology Market Share (%), By Therapeutics, 2017-2031F
Figure 35. Mexico Nanobiotechnology Market Share (%), By Technology, 2017-2031F
Figure 36. Mexico Nanobiotechnology Market Share (%), By Application, 2017-2031F
Figure 37. Mexico Nanobiotechnology Market Share (%), By End-user, 2017-2031F
Figure 38. Europe Nanobiotechnology Market, By Value, In USD Billion, 2017-2031F
Figure 39. Europe Nanobiotechnology Market, By Volume, In Million Units, 2017-2031F
Figure 40. Europe Nanobiotechnology Market Share (%), By Type, 2017-2031F
Figure 41. Europe Nanobiotechnology Market Share (%), By Therapeutics, 2017-2031F
Figure 42. Europe Nanobiotechnology Market Share (%), By Technology, 2017-2031F
Figure 43. Europe Nanobiotechnology Market Share (%), By Application, 2017-2031F
Figure 44. Europe Nanobiotechnology Market Share (%), By End-user, 2017-2031F
Figure 45. Europe Nanobiotechnology Market Share (%), By Country, 2017-2031F
Figure 46. Germany Nanobiotechnology Market, By Value, In USD Billion, 2017-2031F
Figure 47. Germany Nanobiotechnology Market, By Volume, In Million Units, 2017-2031F
Figure 48. Germany Nanobiotechnology Market Share (%), By Type, 2017-2031F
Figure 49. Germany Nanobiotechnology Market Share (%), By Therapeutics, 2017-2031F
Figure 50. Germany Nanobiotechnology Market Share (%), By Technology, 2017-2031F
Figure 51. Germany Nanobiotechnology Market Share (%), By Application, 2017-2031F
Figure 52. Germany Nanobiotechnology Market Share (%), By End-user, 2017-2031F
Figure 53. France Nanobiotechnology Market, By Value, In USD Billion, 2017-2031F
Figure 54. France Nanobiotechnology Market, By Volume, In Million Units, 2017-2031F
Figure 55. France Nanobiotechnology Market Share (%), By Type, 2017-2031F
Figure 56. France Nanobiotechnology Market Share (%), By Therapeutics, 2017-2031F
Figure 57. France Nanobiotechnology Market Share (%), By Technology, 2017-2031F
Figure 58. France Nanobiotechnology Market Share (%), By Application, 2017-2031F
Figure 59. France Nanobiotechnology Market Share (%), By End-user, 2017-2031F
Figure 60. Italy Nanobiotechnology Market, By Value, In USD Billion, 2017-2031F
Figure 61. Italy Nanobiotechnology Market, By Volume, In Million Units, 2017-2031F
Figure 62. Italy Nanobiotechnology Market Share (%), By Type, 2017-2031F
Figure 63. Italy Nanobiotechnology Market Share (%), By Therapeutics, 2017-2031F
Figure 64. Italy Nanobiotechnology Market Share (%), By Technology, 2017-2031F
Figure 65. Italy Nanobiotechnology Market Share (%), By Application, 2017-2031F
Figure 66. Italy Nanobiotechnology Market Share (%), By End-user, 2017-2031F
Figure 67. United Kingdom Nanobiotechnology Market, By Value, In USD Billion, 2017-2031F
Figure 68. United Kingdom Nanobiotechnology Market, By Volume, In Million Units, 2017-2031F
Figure 69. United Kingdom Nanobiotechnology Market Share (%), By Type, 2017-2031F
Figure 70. United Kingdom Nanobiotechnology Market Share (%), By Therapeutics, 2017-2031F
Figure 71. United Kingdom Nanobiotechnology Market Share (%), By Technology, 2017-2031F
Figure 72. United Kingdom Nanobiotechnology Market Share (%), By Application, 2017-2031F
Figure 73. United Kingdom Nanobiotechnology Market Share (%), By End-user, 2017-2031F
Figure 74. Russia Nanobiotechnology Market, By Value, In USD Billion, 2017-2031F
Figure 75. Russia Nanobiotechnology Market, By Volume, In Million Units, 2017-2031F
Figure 76. Russia Nanobiotechnology Market Share (%), By Type, 2017-2031F
Figure 77. Russia Nanobiotechnology Market Share (%), By Therapeutics, 2017-2031F
Figure 78. Russia Nanobiotechnology Market Share (%), By Technology, 2017-2031F
Figure 79. Russia Nanobiotechnology Market Share (%), By Application, 2017-2031F
Figure 80. Russia Nanobiotechnology Market Share (%), By End-user, 2017-2031F
Figure 81. Netherlands Nanobiotechnology Market, By Value, In USD Billion, 2017-2031F
Figure 82. Netherlands Nanobiotechnology Market, By Volume, In Million Units, 2017-2031F
Figure 83. Netherlands Nanobiotechnology Market Share (%), By Type, 2017-2031F
Figure 84. Netherlands Nanobiotechnology Market Share (%), By Therapeutics, 2017-2031F
Figure 85. Netherlands Nanobiotechnology Market Share (%), By Technology, 2017-2031F
Figure 86. Netherlands Nanobiotechnology Market Share (%), By Application, 2017-2031F
Figure 87. Netherlands Nanobiotechnology Market Share (%), By End-user, 2017-2031F
Figure 88. Spain Nanobiotechnology Market, By Value, In USD Billion, 2017-2031F
Figure 89. Spain Nanobiotechnology Market, By Volume, In Million Units, 2017-2031F
Figure 90. Spain Nanobiotechnology Market Share (%), By Type, 2017-2031F
Figure 91. Spain Nanobiotechnology Market Share (%), By Therapeutics, 2017-2031F
Figure 92. Spain Nanobiotechnology Market Share (%), By Technology, 2017-2031F
Figure 93. Spain Nanobiotechnology Market Share (%), By Application, 2017-2031F
Figure 94. Spain Nanobiotechnology Market Share (%), By End-user, 2017-2031F
Figure 95. Turkey Nanobiotechnology Market, By Value, In USD Billion, 2017-2031F
Figure 96. Turkey Nanobiotechnology Market, By Volume, In Million Units, 2017-2031F
Figure 97. Turkey Nanobiotechnology Market Share (%), By Type, 2017-2031F
Figure 98. Turkey Nanobiotechnology Market Share (%), By Therapeutics, 2017-2031F
Figure 99. Turkey Nanobiotechnology Market Share (%), By Technology, 2017-2031F
Figure 100. Turkey Nanobiotechnology Market Share (%), By Application, 2017-2031F
Figure 101. Turkey Nanobiotechnology Market Share (%), By End-user, 2017-2031F
Figure 102. Poland Nanobiotechnology Market, By Value, In USD Billion, 2017-2031F
Figure 103. Poland Nanobiotechnology Market, By Volume, In Million Units, 2017-2031F
Figure 104. Poland Nanobiotechnology Market Share (%), By Type, 2017-2031F
Figure 105. Poland Nanobiotechnology Market Share (%), By Therapeutics, 2017-2031F
Figure 106. Poland Nanobiotechnology Market Share (%), By Technology, 2017-2031F
Figure 107. Poland Nanobiotechnology Market Share (%), By Application, 2017-2031F
Figure 108. Poland Nanobiotechnology Market Share (%), By End-user, 2017-2031F
Figure 109. South America Nanobiotechnology Market, By Value, In USD Billion, 2017-2031F
Figure 110. South America Nanobiotechnology Market, By Volume, In Million Units, 2017-2031F
Figure 111. South America Nanobiotechnology Market Share (%), By Type, 2017-2031F
Figure 112. South America Nanobiotechnology Market Share (%), By Therapeutics, 2017-2031F
Figure 113. South America Nanobiotechnology Market Share (%), By Technology, 2017-2031F
Figure 114. South America Nanobiotechnology Market Share (%), By Application, 2017-2031F
Figure 115. South America Nanobiotechnology Market Share (%), By End-user, 2017-2031F
Figure 116. South America Nanobiotechnology Market Share (%), By Country, 2017-2031F
Figure 117. Brazil Nanobiotechnology Market, By Value, In USD Billion, 2017-2031F
Figure 118. Brazil Nanobiotechnology Market, By Volume, In Million Units, 2017-2031F
Figure 119. Brazil Nanobiotechnology Market Share (%), By Type, 2017-2031F
Figure 120. Brazil Nanobiotechnology Market Share (%), By Therapeutics, 2017-2031F
Figure 121. Brazil Nanobiotechnology Market Share (%), By Technology, 2017-2031F
Figure 122. Brazil Nanobiotechnology Market Share (%), By Application, 2017-2031F
Figure 123. Brazil Nanobiotechnology Market Share (%), By End-user, 2017-2031F
Figure 124. Argentina Nanobiotechnology Market, By Value, In USD Billion, 2017-2031F
Figure 125. Argentina Nanobiotechnology Market, By Volume, In Million Units, 2017-2031F
Figure 126. Argentina Nanobiotechnology Market Share (%), By Type, 2017-2031F
Figure 127. Argentina Nanobiotechnology Market Share (%), By Therapeutics, 2017-2031F
Figure 128. Argentina Nanobiotechnology Market Share (%), By Technology, 2017-2031F
Figure 129. Argentina Nanobiotechnology Market Share (%), By Application, 2017-2031F
Figure 130. Argentina Nanobiotechnology Market Share (%), By End-user, 2017-2031F
Figure 131. Asia-Pacific Nanobiotechnology Market, By Value, In USD Billion, 2017-2031F
Figure 132. Asia-Pacific Nanobiotechnology Market, By Volume, In Million Units, 2017-2031F
Figure 133. Asia-Pacific Nanobiotechnology Market Share (%), By Type, 2017-2031F
Figure 134. Asia-Pacific Nanobiotechnology Market Share (%), By Therapeutics, 2017-2031F
Figure 135. Asia-Pacific Nanobiotechnology Market Share (%), By Technology, 2017-2031F
Figure 136. Asia-Pacific Nanobiotechnology Market Share (%), By Application, 2017-2031F
Figure 137. Asia- Pacific Nanobiotechnology Market Share (%), By End-user, 2017-2031F
Figure 138. Asia-Pacific Nanobiotechnology Market Share (%), By Country, 2017-2031F
Figure 139. India Nanobiotechnology Market, By Value, In USD Billion, 2017-2031F
Figure 140. India Nanobiotechnology Market, By Volume, In Million Units, 2017-2031F
Figure 141. India Nanobiotechnology Market Share (%), By Type, 2017-2031F
Figure 142. India Nanobiotechnology Market Share (%), By Therapeutics, 2017-2031F
Figure 143. India Nanobiotechnology Market Share (%), By Technology, 2017-2031F
Figure 144. India Nanobiotechnology Market Share (%), By Application, 2017-2031F
Figure 145. India Nanobiotechnology Market Share (%), By End-user, 2017-2031F
Figure 146. China Nanobiotechnology Market, By Value, In USD Billion, 2017-2031F
Figure 147. China Nanobiotechnology Market, By Volume, In Million Units, 2017-2031F
Figure 148. China Nanobiotechnology Market Share (%), By Type, 2017-2031F
Figure 149. China Nanobiotechnology Market Share (%), By Therapeutics, 2017-2031F
Figure 150. China Nanobiotechnology Market Share (%), By Technology, 2017-2031F
Figure 151. China Nanobiotechnology Market Share (%), By Application, 2017-2031F
Figure 152. China Nanobiotechnology Market Share (%), By End-user, 2017-2031F
Figure 153. Japan Nanobiotechnology Market, By Value, In USD Billion, 2017-2031F
Figure 154. Japan Nanobiotechnology Market, By Volume, In Million Units, 2017-2031F
Figure 155. Japan Nanobiotechnology Market Share (%), By Type, 2017-2031F
Figure 156. Japan Nanobiotechnology Market Share (%), By Therapeutics, 2017-2031F
Figure 157. Japan Nanobiotechnology Market Share (%), By Technology, 2017-2031F
Figure 158. Japan Nanobiotechnology Market Share (%), By Application, 2017-2031F
Figure 159. Japan Nanobiotechnology Market Share (%), By End-user, 2017-2031F
Figure 160. Australia Nanobiotechnology Market, By Value, In USD Billion, 2017-2031F
Figure 161. Australia Nanobiotechnology Market, By Volume, In Million Units, 2017-2031F
Figure 162. Australia Nanobiotechnology Market Share (%), By Type, 2017-2031F
Figure 163. Australia Nanobiotechnology Market Share (%), By Therapeutics, 2017-2031F
Figure 164. Australia Nanobiotechnology Market Share (%), By Technology, 2017-2031F
Figure 165. Australia Nanobiotechnology Market Share (%), By Application, 2017-2031F
Figure 166. Australia Nanobiotechnology Market Share (%), By End-user, 2017-2031F
Figure 167. Vietnam Nanobiotechnology Market, By Value, In USD Billion, 2017-2031F
Figure 168. Vietnam Nanobiotechnology Market, By Volume, In Million Units, 2017-2031F
Figure 169. Vietnam Nanobiotechnology Market Share (%), By Type, 2017-2031F
Figure 170. Vietnam Nanobiotechnology Market Share (%), By Therapeutics, 2017-2031F
Figure 171. Vietnam Nanobiotechnology Market Share (%), By Technology, 2017-2031F
Figure 172. Vietnam Nanobiotechnology Market Share (%), By Application, 2017-2031F
Figure 173. Vietnam Nanobiotechnology Market Share (%), By End-user, 2017-2031F
Figure 174. South Korea Nanobiotechnology Market, By Value, In USD Billion, 2017-2031F
Figure 175. South Korea Nanobiotechnology Market, By Volume, In Million Units, 2017-2031F
Figure 176. South Korea Nanobiotechnology Market Share (%), By Type, 2017-2031F
Figure 177. South Korea Nanobiotechnology Market Share (%), By Therapeutics, 2017-2031F
Figure 178. South Korea Nanobiotechnology Market Share (%), By Technology, 2017-2031F
Figure 179. South Korea Nanobiotechnology Market Share (%), By Application, 2017-2031F
Figure 180. South Korea Nanobiotechnology Market Share (%), By End-user, 2017-2031F
Figure 181. Indonesia Nanobiotechnology Market, By Value, In USD Billion, 2017-2031F
Figure 182. Indonesia Nanobiotechnology Market, By Volume, In Million Units, 2017-2031F
Figure 183. Indonesia Nanobiotechnology Market Share (%), By Type, 2017-2031F
Figure 184. Indonesia Nanobiotechnology Market Share (%), By Therapeutics, 2017-2031F
Figure 185. Indonesia Nanobiotechnology Market Share (%), By Technology, 2017-2031F
Figure 186. Indonesia Nanobiotechnology Market Share (%), By Application, 2017-2031F
Figure 187. Indonesia Nanobiotechnology Market Share (%), By End-user, 2017-2031F
Figure 188. Philippines Nanobiotechnology Market, By Value, In USD Billion, 2017-2031F
Figure 189. Philippines Nanobiotechnology Market, By Volume, In Million Units, 2017-2031F
Figure 190. Philippines Nanobiotechnology Market Share (%), By Type, 2017-2031F
Figure 191. Philippines Nanobiotechnology Market Share (%), By Therapeutics, 2017-2031F
Figure 192. Philippines Nanobiotechnology Market Share (%), By Technology, 2017-2031F
Figure 193. Philippines Nanobiotechnology Market Share (%), By Application, 2017-2031F
Figure 194. Philippines Nanobiotechnology Market Share (%), By End-user, 2017-2031F
Figure 195. Middle East & Africa Nanobiotechnology Market, By Value, In USD Billion, 2017-2031F
Figure 196. Middle East & Africa Nanobiotechnology Market, By Volume, In Million Units, 2017-2031F
Figure 197. Middle East & Africa Nanobiotechnology Market Share (%), By Type, 2017-2031F
Figure 198. Middle East & Africa Nanobiotechnology Market Share (%), By Therapeutics, 2017-2031F
Figure 199. Middle East & Africa Nanobiotechnology Market Share (%), By Technology, 2017-2031F
Figure 200. Middle East & Africa Nanobiotechnology Market Share (%), By Application, 2017-2031F
Figure 201. Middle East & Africa Nanobiotechnology Market Share (%), By End-user, 2017-2031F
Figure 202. Middle East & Africa Nanobiotechnology Market Share (%), By Country, 2017-2031F
Figure 203. Saudi Arabia Nanobiotechnology Market, By Value, In USD Billion, 2017-2031F
Figure 204. Saudi Arabia Nanobiotechnology Market, By Volume, In Million Units, 2017-2031F
Figure 205. Saudi Arabia Nanobiotechnology Market Share (%), By Type, 2017-2031F
Figure 206. Saudi Arabia Nanobiotechnology Market Share (%), By Therapeutics, 2017-2031F
Figure 207. Saudi Arabia Nanobiotechnology Market Share (%), By Technology, 2017-2031F
Figure 208. Saudi Arabia Nanobiotechnology Market Share (%), By Application, 2017-2031F
Figure 209. Saudi Arabia Nanobiotechnology Market Share (%), By End-user, 2017-2031F
Figure 210. UAE Nanobiotechnology Market, By Value, In USD Billion, 2017-2031F
Figure 211. UAE Nanobiotechnology Market, By Volume, In Million Units, 2017-2031F
Figure 212. UAE Nanobiotechnology Market Share (%), By Type, 2017-2031F
Figure 213. UAE Nanobiotechnology Market Share (%), By Therapeutics, 2017-2031F
Figure 214. UAE Nanobiotechnology Market Share (%), By Technology, 2017-2031F
Figure 215. UAE Nanobiotechnology Market Share (%), By Application, 2017-2031F
Figure 216. UAE Nanobiotechnology Market Share (%), By End-user, 2017-2031F
Figure 217. South Africa Nanobiotechnology Market, By Value, In USD Billion, 2017-2031F
Figure 218. South Africa Nanobiotechnology Market, By Volume, In Million Units, 2017-2031F
Figure 219. South Africa Nanobiotechnology Market Share (%), By Type, 2017-2031F
Figure 220. South Africa Nanobiotechnology Market Share (%), By Therapeutics, 2017-2031F
Figure 221. South Africa Nanobiotechnology Market Share (%), By Technology, 2017-2031F
Figure 222. South Africa Nanobiotechnology Market Share (%), By Application, 2017-2031F
Figure 223. South Africa Nanobiotechnology Market Share (%), By End-user, 2017-2031F
Figure 224. By Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 225. By Therapeutics Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 226. By Technology Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 227. By Application Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 228. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 229. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023

Product Code: MX10940

Global nanobiotechnology market size was valued at USD 75.8 billion in 2023, expected to reach USD 143.1 billion in 2031, with a CAGR of 8.27% for the forecast period between 2024 and 2031F. Technological advancements propel the growth of the global nanobiotechnology market, amplify R&D investments, expand uses in healthcare and medicine, and increase the need for personalized medicine and precise drug delivery systems. Moreover, the merging of nanotechnology and biotechnology has sparked advancements in diagnostics, therapeutics, and biomedical research, contributing significantly to market expansion.

The robust expansion of the global nanobiotechnology market relies on various pivotal factors. Foremost, the ongoing progression of technological advancements continually pushes the boundaries of innovation. Nanoscale science and engineering breakthroughs have unlocked unparalleled opportunities, fostering the emergence of fresh tools and methodologies in the domain of nanobiotechnology. Concurrently, heightened investments in research and development (R&D) across diverse sectors have propelled the evolution of nanobiotechnology. These substantial investments drive explorations into novel applications, materials, and methodologies, amplifying the potential for groundbreaking discoveries in healthcare and medicine. The increasing integration of nanotechnology in healthcare and medicine serves as a linchpin for expanding the global nanobiotechnology market.

Nanotechnology's adaptability in these arenas facilitates notable strides in diagnostics, presenting highly sensitive and precise tools for early disease identification. Additionally, in therapeutics, nanobiotechnology transforms drug delivery systems by enabling targeted and controlled medication release, improving treatment effectiveness while minimizing adverse effects. The rising demand for tailored medicine and precise drug delivery systems further propels the growth of global nanobiotechnology market. Nanotechnology's ability to customize treatments and interventions aligns perfectly with the escalating need, fostering the development of therapies personalized to an individual's distinct genetic composition or specific health conditions. Moreover, the convergence of nanotechnology and biotechnology acts as a catalyst, driving breakthroughs in diagnostics, therapeutics, and biomedical research. This fusion fuel innovation, expanding the realm of possibilities in nanobiotechnology and significantly contributing to the expansion and progression of global nanobiotechnology market.

Expanding Uses in Healthcare and Medicine

The increasing incorporation of nanotechnology in healthcare and medicine is a fundamental catalyst for the growing global nanobiotechnology market. Nanotechnology's application in these domains encompasses diverse advancements, particularly in diagnostics, therapeutics, and biomedical research. In diagnostics, nanomaterials facilitate the development of exceptionally sensitive and precise diagnostic instruments, enabling early disease detection with outstanding accuracy. Nanobiotechnology transforms drug delivery systems regarding therapeutics, heightening effectiveness while reducing side effects through targeted and precise release of medicinal compounds. Moreover, nanoscale materials drive the innovation of novel treatments, encompassing nano-formulations for various illnesses, gene therapy, and advancements in regenerative medicine. The fusion of nanotechnology and biotechnology has spurred breakthroughs in biomedical research, fostering sophisticated tools to examine biological systems at a molecular level. These strides facilitate the creation of pioneering medical solutions, propelling the global nanobiotechnology market by promising to reshape healthcare delivery and improve outcomes on a global scale.

Amplified Research and Development Investments

Augmented research and development funding significantly drives the global nanobiotechnology market forward. These increased investments stimulate innovative research, nurturing progress in nanoscale technologies, materials, and approaches. They spark pivotal advancements in healthcare, leading to the development of accurate diagnostic tools, specialized drug delivery systems, and tailored treatments. Through the amplification of R&D funding, the market gains from heightened innovation, expanding the frontiers of nanobiotechnology to provide groundbreaking solutions for healthcare, medicine, and biomedical research worldwide.

For instance, in July 2023, McGill University stated that it had agreements in place to fund two innovative research projects involving lipid nanoparticles (LNPs) with Moderna, Inc., a biotechnology company that is leading the way in messenger RNA (mRNA) therapies and vaccines. Since LNPs are the main means of delivering mRNA strands to the target cells, they play a crucial role in mRNA therapeutics like vaccinations.

Government Initiatives

Governments globally are proactively executing diverse strategies to drive the advancement of the global nanobiotechnology market. These initiatives involve significant financial commitments directed towards research and development, stimulating progress in nanoscale technologies. Furthermore, governments institute favorable policies, frameworks, and partnerships to propel nanobiotechnology forward. They foster collaborations between academia, industry, and research entities, fostering knowledge sharing and hastening market expansion. Additionally, governments allocate resources towards infrastructure and offer incentives, aiming to promote the uptake and commercial viability of nanobiotechnology. The concerted effort supports its broad-ranging implementation across sectors like healthcare, medicine, agriculture, and environmental sustainability.

For instance, the National Nanotechnology Initiative (NNI) in the United States was requested to receive USD 1.99 billion in the President's 2023 Budget in February 2023. Since the NNI's founding in 2001, the total requested, including the 2023 request, has exceeded USD 40.7 billion. The National Nanotechnology Initiative (NNI) is a research and development (R&D) program of the United States government. In addition to supporting a shared infrastructure, enabling resource leveraging without duplication, and establishing shared goals, priorities, and strategies that support agency-specific missions and activities, the NNI improves interagency coordination of nanoscale R&D.

Use of Nanotechnology in Drug Delivery

The rising need for nanotechnology in delivering drugs serves as a key catalyst driving the growth of global nanobiotechnology market. Nanotechnology's role in drug delivery allows for precise, targeted drug application, improving effectiveness while reducing potential side effects. The growing demand arises from nanoscale materials' ability to encapsulate medications, ensure their safe delivery to precise cells or tissues. Additionally, nanotechnology enables controlled release methods, improving therapeutic results. The increasing dependence on nanotechnology in drug delivery underscores its importance, fostering advancements and growth in the nanobiotechnology market, reshaping medication administration for better healthcare outcomes worldwide. To speed up the development of nucleic acid-based medicines and vaccines, Mana.bio, a biotechnology startup that accelerates programmable drug delivery, for instance, announced its AI-based lipid nanoparticle (LNP) delivery platform in October 2023, underwritten by a USD 19.5 million oversubscribed seed rounds. With the funding, Mana.bio may continue developing its unique, specially designed AI LNP platform, which could potentially lead to the creation of novel treatments for a variety of unmet needs by delivering RNA and gene therapies to extrahepatic tissues in the body in a safer and more efficient manner.

Growing Popularity of Nanoparticles

The increasing requirement for nanoparticles acts as a substantial driving factor in advancing the global nanobiotechnology market. These tiny entities hold a central position across diverse fields, notably in healthcare, medicine, and materials science. Their distinct characteristics facilitate precise drug administration, improving treatment effectiveness while reducing adverse effects. Moreover, nanoparticles find utility in diagnostics, imaging, and various industrial domains. The rising interest in these adaptable particles emphasizes their significance in propelling nanobiotechnology, encouraging breakthroughs that transform healthcare methodologies, advanced material development, and a broad range of industrial applications, thereby impacting the market's growth and development. A benchtop instrument for detailed analysis of lipid nanoparticles and other nano-formulations, for example, is scheduled to be launched in September 2023 by SPARTA Biodiscovery, a spin-out company from Imperial College London. According to Jelle Penders, PhD, co-inventor of Single Particle Automated Raman Trapping Analysis (SPARTA), the instrument is the first to simultaneously identify the composition and size of nano-formulations in an automated and label-free manner.

Future Market Scenario

The global nanobiotechnology market's future holds remarkable promise, driven by ongoing innovations and evolving applications. Nanobiotechnology leads the forefront of scientific advancement, offering revolutionary changes across numerous industries. In healthcare, it facilitates precise drug delivery, personalized medicine, and advanced diagnostics, improving treatments with reduced side effects. Its impact spans environmental remediation, agriculture, electronics, and energy sectors, revolutionizing material science and manufacturing processes. Continual research and development efforts, along with increased global investments, drive market expansion. Advancing technology and interdisciplinary collaborations further unlock nanobiotechnology's potential, addressing previously insurmountable challenges. Moreover, the convergence of nanotechnology, biotechnology, and information technology foretells a new era, where nanobiotechnology becomes pivotal in addressing global health, environmental, and societal concerns. The trajectory signifies a promising and transformative path for the global nanobiotechnology market.

Key Players Landscape and Outlook

Key players in the global nanobiotechnology market proactively participate in collaborative endeavors encompassing strategic alliances, joint research initiatives, and shared investments. Their goal is to collectively leverage resources, expertise, and technological advancements, driving innovation and broadening the horizons of nanobiotechnology applications. These collaborative initiatives allow for the harnessing of complementary strengths, enabling the creation of innovative products and solutions. Furthermore, these partnerships facilitate market exploration across diverse industries and consumer segments, fostering the widespread adoption of nanobiotechnology. It amplifies its influence not only in healthcare, materials science, and environmental sustainability but also in various other domains.

In March 2023, for example, Moderna announced that it had applied for Generation Bio's exclusive stealth cell-targeted lipid nanoparticle (ctLNP) delivery system to find and create non-viral genetic medicines for liver and immune system disorders. This partnership could bring in up to $1.876 billion for Generation Bio. Moderna has obtained the option to license the closed-end DNA (ceDNA) novel build technology from Generation Bio as well as ctLNP.

1. Research Methodology

2. Project Scope & Definitions

3. Executive Summary

4. Global Nanobiotechnology Market Outlook, 2017-2031F

4.1. Market Size & Forecast
- 4.1.1. Value
- 4.1.2. Volume
4.2. By Type
- 4.2.1. 0-10 Nm
- 4.2.2. 10-100 Nm
4.3. By Therapeutics
- 4.3.1. Dental Therapies
- 4.3.2. Cardiac Therapies
- 4.3.3. Orthopedic Therapies
- 4.3.4. Others
4.4. By Technology
- 4.4.1. Nanocrystals
- 4.4.2. Nanoparticles
- 4.4.3. Liposomes
- 4.4.4. Micelles
- 4.4.5. Nanotubes
- 4.4.6. Others
4.5. By Application
- 4.5.1. Therapeutics
- 4.5.2. Nano diagnostics
- 4.5.3. Tissue Engineering
- 4.5.4. Gene Therapy
- 4.5.5. Molecular Nanotechnology
- 4.5.6. Drug Delivery
- 4.5.7. Food Safety
4.6. By End-user
- 4.6.1. Pharmaceutical Companies
- 4.6.2. Research Institutes and Laboratories
- 4.6.3. Academic Institutions
- 4.6.4. Others
4.7. By Region
- 4.7.1. North America
- 4.7.2. Europe
- 4.7.3. South America
- 4.7.4. Asia-Pacific
- 4.7.5. Middle East and Africa
4.8. By Company Market Share (%), 2023

5. Global Nanobiotechnology Market Outlook, By Region, 2017-2031F

5.1. North America*
- 5.1.1. Market Size & Forecast
  - 5.1.1.1. Value
  - 5.1.1.2. Volume
- 5.1.2. By Type
  - 5.1.2.1. 0-10 Nm
  - 5.1.2.2. 10-100 Nm
- 5.1.3. By Therapeutics
  - 5.1.3.1. Dental Therapies
  - 5.1.3.2. Cardiac Therapies
  - 5.1.3.3. Orthopedic Therapies
  - 5.1.3.4. Others
- 5.1.4. By Technology
  - 5.1.4.1. Nanocrystals
  - 5.1.4.2. Nanoparticles
  - 5.1.4.3. Liposomes
  - 5.1.4.4. Micelles
  - 5.1.4.5. Nanotubes
  - 5.1.4.6. Others
- 5.1.5. By Application
  - 5.1.5.1. Therapeutics
  - 5.1.5.2. Nano diagnostics
  - 5.1.5.3. Tissue Engineering
  - 5.1.5.4. Gene Therapy
  - 5.1.5.5. Molecular Nanotechnology
  - 5.1.5.6. Drug Delivery
  - 5.1.5.7. Food Safety
- 5.1.6. By End-user
  - 5.1.6.1. Pharmaceutical Companies
  - 5.1.6.2. Research Institutes and Laboratories
  - 5.1.6.3. Academic Institutions
  - 5.1.6.4. Others
- 5.1.7. United States*
  - 5.1.7.1. Market Size & Forecast
  - 5.1.7.1.1. Value
  - 5.1.7.1.2. Volume
  - 5.1.7.2. By Type
  - 5.1.7.2.1. 0-10 Nm
  - 5.1.7.2.2. 10-100 Nm
  - 5.1.7.3. By Therapeutics
  - 5.1.7.3.1. Dental Therapies
  - 5.1.7.3.2. Cardiac Therapies
  - 5.1.7.3.3. Orthopedic Therapies
  - 5.1.7.3.4. Others
  - 5.1.7.4. By Technology
  - 5.1.7.4.1. Nanocrystals
  - 5.1.7.4.2. Nanoparticles
  - 5.1.7.4.3. Liposomes
  - 5.1.7.4.4. Micelles
  - 5.1.7.4.5. Nanotubes
  - 5.1.7.4.6. Others
  - 5.1.7.5. By Application
  - 5.1.7.5.1. Therapeutics
  - 5.1.7.5.2. Nano diagnostics
  - 5.1.7.5.3. Tissue Engineering
  - 5.1.7.5.4. Gene Therapy
  - 5.1.7.5.5. Molecular Nanotechnology
  - 5.1.7.5.6. Drug Delivery
  - 5.1.7.5.7. Food Safety
  - 5.1.7.6. By End-user
  - 5.1.7.6.1. Pharmaceutical Companies
  - 5.1.7.6.2. Research Institutes and Laboratories
  - 5.1.7.6.3. Academic Institutions
  - 5.1.7.6.4. Others
- 5.1.8. Canada
- 5.1.9. Mexico

All segments will be provided for all regions and countries covered:

5.2. Europe
- 5.2.1. Germany
- 5.2.2. France
- 5.2.3. Italy
- 5.2.4. United Kingdom
- 5.2.5. Russia
- 5.2.6. Netherlands
- 5.2.7. Spain
- 5.2.8. Turkey
- 5.2.9. Poland
5.3. South America
- 5.3.1. Brazil
- 5.3.2. Argentina
5.4. Asia-Pacific
- 5.4.1. India
- 5.4.2. China
- 5.4.3. Japan
- 5.4.4. Australia
- 5.4.5. Vietnam
- 5.4.6. South Korea
- 5.4.7. Indonesia
- 5.4.8. Philippines
5.5. Middle East & Africa
- 5.5.1. Saudi Arabia
- 5.5.2. UAE
- 5.5.3. South Africa

6. Market Mapping, 2023

6.1. By Type
6.2. By Therapeutics
6.3. By Technology
6.4. By Application
6.5. By End-user
6.6. By Region

7. Macro Environment and Industry Structure

7.1. Supply Demand Analysis
7.2. Import Export Analysis
7.3. Value Chain Analysis
7.4. PESTEL Analysis
- 7.4.1. Political Factors
- 7.4.2. Economic System
- 7.4.3. Social Implications
- 7.4.4. Technological Advancements
- 7.4.5. Environmental Impacts
- 7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
7.5. Porter's Five Forces Analysis
- 7.5.1. Supplier Power
- 7.5.2. Buyer Power
- 7.5.3. Substitution Threat
- 7.5.4. Threat from New Entrant
- 7.5.5. Competitive Rivalry

8. Market Dynamics

8.1. Growth Drivers
8.2. Growth Inhibitors (Challenges and Restraints)

9. Regulatory Framework and Innovation

9.1. Clinical Trials
9.2. Patent Landscape
9.3. Regulatory Approvals
9.4. Innovations/Emerging Technologies

10. Key Players Landscape

10.1. Competition Matrix of Top Five Market Leaders
10.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
10.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
10.4. SWOT Analysis (For Five Market Players)
10.5. Patent Analysis (If Applicable)

11. Pricing Analysis

12. Case Studies

13. Key Players Outlook

13.1. Moderna, Inc.
- 13.1.1. Company Details
- 13.1.2. Key Management Personnel
- 13.1.3. Products & Services
- 13.1.4. Financials (As reported)
- 13.1.5. Key Market Focus & Geographical Presence
- 13.1.6. Recent Developments
13.2. Generation Bio Co.
13.3. Sanofi S.A.
13.4. GlaxoSmithKline Plc
13.5. Arrowhead Pharmaceuticals Inc.
13.6. Bristol-Myers Squibb Company
13.7. Merck & Co. Inc.
13.8. BlueWillow Biologics, Inc.
13.9. pSivida Corp.
13.10. Merck KGaA
13.11. Starpharma Holdings Ltd.
13.12. Thermo Fisher Scientific Inc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

ナノバイオテクノロジーの世界市場：タイプ別、治療法別、技術別、用途別、エンドユーザー別、地域別、機会、予測、2017年～2031年

Nanobiotechnology Market Assessment, By Type, By Therapeutics, By Technology, By Application, By End-user, By Region, Opportunities and Forecast, 2017-2031F

目次

第1章 調査手法

第2章 プロジェクトの範囲と定義

第3章 エグゼクティブサマリー

第4章 世界のナノバイオテクノロジー市場の見通し、2017年～2031年

第5章 世界のナノバイオテクノロジー市場の見通し、地域別、2017年～2031年

第6章 市場マッピング、2023年

第7章 マクロ環境と産業構造

第8章 市場力学

第9章 規制の枠組みとイノベーション

第10章 主要参入企業の情勢

第11章 価格分析

第12章 ケーススタディ

第13章 主要企業の見通し

第14章 戦略的提言

第15章 お問合せと免責事項

List of Tables

List of Figures

Expanding Uses in Healthcare and Medicine

Amplified Research and Development Investments

Government Initiatives

Use of Nanotechnology in Drug Delivery

Growing Popularity of Nanoparticles

Future Market Scenario

Key Players Landscape and Outlook

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Executive Summary

4. Global Nanobiotechnology Market Outlook, 2017-2031F

5. Global Nanobiotechnology Market Outlook, By Region, 2017-2031F

6. Market Mapping, 2023

7. Macro Environment and Industry Structure

8. Market Dynamics

9. Regulatory Framework and Innovation

10. Key Players Landscape

11. Pricing Analysis

12. Case Studies

13. Key Players Outlook

14. Strategic Recommendations

15. About Us & Disclaimer

第1章調査手法

第2章プロジェクトの範囲と定義

第3章エグゼクティブサマリー

第4章世界のナノバイオテクノロジー市場の見通し、2017年～2031年

第5章世界のナノバイオテクノロジー市場の見通し、地域別、2017年～2031年

第6章市場マッピング、2023年

第7章マクロ環境と産業構造

第8章市場力学

第9章規制の枠組みとイノベーション

第10章主要参入企業の情勢

第11章価格分析

第12章ケーススタディ

第13章主要企業の見通し

第14章戦略的提言

第15章お問合せと免責事項